Surgery Websites
LiverSource »  Faculty »  Transplant Surgery »  Peter G. Stock, M.D., Ph.D.

Peter G. Stock, M.D., Ph.D.

Professor of Surgery
Surgical Director, Kidney and Pancreas Transplant Program
Surgical Director, Pediatric Renal Transplant Program
Co-Director, Pancreatic Islet Cell Transplant Program
Program, Director, T32 Training Program in Transplant Surgery

Contact Information

Academic Office
(415) 353-8617
peter.stock@ucsf.edu
Open Popup

Education

  • University of Illinois, Urbana, IL, B.S., Biology, 1974-78
  • University of Illinois, Chicago, IL, M.D., Medicine, 1978-82
  • University of Minnesota, Minneapolis, MN, Ph.D., Surgery, 1985-92

Residencies

  • University of Minnesota, Intern, General Surgery, 1982-83
  • University of Minnesota, Resident, General Surgery, 1983-90

Fellowships

  • University of California, San Francisco, Fellow, Transplant Surgery, 1990-92

Board Certifications

  • American Board of Surgery, 1991

Program Affiliations

Clinical Expertise

  • Bile Duct Injuries
  • Bile Duct Strictures
  • Cholangiocarcinoma (Bile Duct Cancer)
  • Choledochal Cyst Disease
  • Dialysis Access
  • End-Stage Kidney Disease
  • Fulminant Hepatic Failure
  • Hepatitis B
  • Hepatitis C
  • Hepatocellular Carcinoma (Liver Cancer)
  • Kidney and LIver Transplantation in HIV Patients
  • Kidney Transplantation
  • Liver Transplantation
  • Living Donor Kidney Transplantation
  • Living Donor Liver Transplantation
  • Pancreas Transplantation
  • Pancreatic Islet Cell Transplantation
  • Pediatric Kidney Transplantation
  • Pediatric Liver Transplantation
  • Polycystic Kidney Disease
  • Polycystic Liver Disease
  • Portal Hypertension

Research Interests

  • Induction of transplantation tolerance to block alloimmunity and recurrent autoimmunity following pancreatic islet transplantation
  • Safety and efficacy of solid organ transplantation in people with HIV

Biography

Peter G. Stock, M.D., Ph.D. is Professor of Surgery at UCSF, Surgical Director of the Pediatric Renal Transplantation Program and Surgical Director of the Pancreas Transplant Program. He was trained at the University of Minnesota, completing a surgical residency before coming to UCSF for a transplant fellowship. He joined the UCSF faculty in 1992. Dr. Stock specializes in liver, kidney and pancreas transplantation.

For many years, Dr. Stock was Chair of the Department of Surgery Research Committee. Under his  outstanding leadership. he has helped to establish UCSF Surgery as one of the top research programs for surgical residents in the U.S.

A clincial investigation on which Dr. Stock served as principal investigator led the passage of the Hope Act lifting the ban on research for transplanting organs between HIV-positive donors and recipients.

Dr. Stock is a frequent presenter on issues related to transplantation and immunosuppression, and holds membership in numerous professional and honorary societies.

Awards & Honors

  • James IVth Fellowship Award, US Representative, 2000
  • Faculty Fellowship Award, American College of Surgeons, 1993
  • Sandoz Fellowship Award, American Society of Transplant Surgeons, 1991
  • Outstanding Surgical Resident Teaching Award, Department of Surgery, University of Minnesota, Minneapolis, MN, 1989
  • David Gaviser Award, Outstanding Surgical Research, University of Minnesota, Minneapolis, MN, 1989
  • Outstanding Research Award, Senior Medical Student, University of Illinois, Chicago, IL, 1982
  • Alpha Omega Alpha, University of Illinois, Chicago, IL, 1981
  • Magna Cum Laude, Honors in Biology with High Distinction, University of Illinois, Urbana, IL, 1978
  • Phi Beta Kappa, University of Illinois, Urbana, IL, 1978
View all

Research Overview

Pancreatic Islet Transplantation
The translational research in the field of pancreatic islets revolves around clinical trials of the safety and efficacy of islet transplantation in patients with Type I diabetes. The clinical trials are funded by the National Institutes of Health (NIH) and the Juvenile Diabetes Research Foundation (JDRF). These clinical trials focus on novel immunosuppressive strategies that utilize co-stimulatory blockade to prevent the immune response against pancreatic islets with a regimen that is not toxic to kidneys or beta cells.

Related research involves improving the techniques required for isolating pancreatic islets from the pancreas, which is being conducted in a fully compliant GMP laboratory facility. The study of the alloimmune and autoimmune response following islet transplantation will be conducted to determine the efficacy of the immunosuppressive strategies. Further translational studies will include methods of expanding the source of beta cells, using direct proliferation, as well as manipulation of precursor cells localized in the adult pancreas. We are currently funded (PI) for a translational grant from California Institute of Regenerative Medicine (CIRM) to bring embryonic stem cell-derived beta cells to a clinical trial.

Solid Organ Transplantation in People with HIV
With the advent of highly active anti-retroviral therapy (HAART), HIV has been a chronic disease. People with HIV are no longer dying from progression of HIV to AIDS, but rather as a result of end stage live disease (viral hepatitis co-infection) and kidney disease (HIV nephropathy). Our laboratory heads up the large NIH-sponsored national multicenter trial which is studying the safety and efficacy of solid organ transplantation in people with HIV. Translational research is exploring the impact of HIV on organ function and the impact of immunosuppression on the immune response against HIV and associated copathogens.

Research Pathways

Research Activities & Funding

Data provided by UCSF Profiles, powered by CTSI

Clinical Trials

Data provided by UCSF Profiles, powered by CTSI

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 231
Data provided by UCSF Profiles, powered by CTSI
  1. Stock PG, Wall A, Gardner J, Domínguez-Gil B, Chadban S, Muller E, Dittmer I, Tullius SG. Ethical Issues in the COVID Era: Doing the Right Thing Depends on Location, Resources, and Disease Burden. Transplantation. 2020 Jul; 104(7):1316-1320. View in PubMed
  2. Mannon RB, Armstrong B, Stock PG, Mehta AK, Farris AB, Watson N, Morrison Y, Sarwal M, Sigdel T, Bridges N, Robien M, Newell KA, Larsen CP. Avoidance of CNI and Steroids Using Belatacept - Results of the Clinical Trials in Organ Transplantation 16 Trial. Am J Transplant. 2020 Jun 18. View in PubMed
  3. Yamanaga S, Freise CE, Stock PG, Rosario A, Fernandez D, Kobayashi T, Tavakol M, Kang SM. Inferior Long-Term Graft Survival of Suboptimal Kidneys After Living Donor Kidney Transplantation. Transplant Proc. 2020 May 20. View in PubMed
  4. Braun HJ, Dodge JL, Grab JD, Schwab ME, Liu IH, Glencer AC, Stock PG, Hirose R, Roberts JP, Ascher NL. Live Donor Liver Transplantation in the United States: Impact of Share 35 on Live Donor Utilization. Transplantation. 2020 May 18. View in PubMed
  5. Wall AE, Pruett T, Stock P, Testa G. Coronavirus disease 2019: Utilizing an ethical framework for rationing absolutely scarce health-care resources in transplant allocation decisions. Am J Transplant. 2020 Apr 13. View in PubMed
  6. View All Publications

Videos

Data provided by UCSF Profiles, powered by CTSI
  1. Consequences of the New Allocation System for Kidney-Pancreas Transplants
  2. Interview with Peter Stock MD, PhD - ASTS President 2014-2015
  3. Transplantation to Cure Diabetes Mellitus: Past, Present, and Future - Update 2019
  4. Interactive Selection Meeting: Who Gets It And Who Doesn't Get It? - UCSF Kidney Transplant Program Update in Transplantation 2018

In the News

  • Diverse Group of Researchers Help Pioneer Novel Approach to Treating Type 1 Diabetes Using Pancreatic Islets and Parathyroid Gland Co-Transplantation

    UCSF News Services - Shelley Wong - June 13, 2019
    Researcher of the Month: Peter Stock, MD, PhD As a pivotal figure in HIV-to-HIV organ transplantation and its legalization through the passage of the HIV Organ Policy Equity (HOPE) Act, transplant surgeon Peter G. Stock, MD., PhD., continues to strive toward breakthroughs in research. While Stock is mostly known for his HIV transplantation work, he has been investigating pancreatic islet transplantation (also known as beta cell replacement) to cure type 1 diabetes since his days as a PhD [...]

  • California Institute for Regenerative Medicine Awards Dr. Peter Stock $11M Grant to Conduct Clinical Trial for Treatment of Type 1 Diabetes

    Stem Cellar, The Official Blog of CIRM, California's Stem Cell Agency - Yimy Villa - May 23, 2019
    The California Institute for Regenerative Medicine (CIRM) awarded $11.08 Million to Dr. Peter Stock at the University of California San Francisco (UCSF) to conduct a clinical trial for treatment of Type 1 Diabetes (T1D)... The trial will be using parathyroid glands to aid in the success and viability of the transplant procedure.  Co-transplantation of islets and parathyroid glands, from the same donor, substantially increases beta cell survival, potentially enabling adequate long-term [...]

  • Department of Surgery Ranks 3rd Nationally in NIH Funding for Surgery Category - Three Surgeon-Scientists Rank in Top 20

    UCSF Department of Surgery - Richard Barg - March 27, 2018
    The UCSF Department of Surgery now ranks No. 3 nationally in NIH research funding among all academic surgery programs, a stunning rise from 6th the last time the survey was done. Three Department of Surgery faculty also ranked in the top 20 of all NIH-funded principal investigators nationally in the category of surgery. The highly respected Blue Ridge Institute for Medical Research utilized data from the Research Portfolio Online Reporting Tool (RePORT) to survey U.S. medical schools for their [...]

  • Transplant Surgeons Sandy Feng and Peter Stock Rank in Top 20 of NIH-Funded Investigators in Surgery for 2017

    UCSF Department of Surgery - Richard Barg - March 12, 2018
    Transplant surgeons Sandy Feng, M.D., Ph.D. and Peter G. Stock, M.D., Ph.D. continued their stellar records of accomplishment in garnering NIH funding for their cutting-edge clinical research, ranking in the top 20 of all NIH-Funded principal investigators in the category of surgery nationally for 2017. Stock ranked 8th and Feng 20th out of 534 investigators nationwide, both in the top 4%, this according to survey data analyzed by the highly respected Blue Ridge Institute for Medical Research. [...]

  • Moving Mountains - A Surgeon’s Fight to Legalize HIV-to-HIV Organ Transplants

    UCSF Transplant Surgery - Richard Barg - June 26, 2017
    President Barack Obama signs the HOPE Act legislation in November 2013. Peter Stock (far left) had earlier testified before Congress in support of the legislation, which overturned a federal ban on HIV-to-HIV transplants. Photo by Evan Vucci UCSF News reports on the epic battle, led by UCSF transplant surgeon Peter G. Stock, M.D., Ph.D., to repeal long-standing federal and state laws banning HIV-to-HIV organ transplantation, this after having served as lead Principal Investigator on [...]

  • NIH Awards Department of Surgery T32 Training Grant for Transplant Surgery

    UCSF Department of Surgery - Richard Barg - January 06, 2017
    The NIH has awarded the UCSF Department of Surgery a T32 training grant, "Filling a Void of Research Training for Transplant Surgeons" (FAVOR). The grant, awarded in August 2016, provides annual funding in the amount of $156,602 for in-depth training of three general surgery residents with an interest in transplant surgery during their two research years, the training to be focused on translational immunology. The program is led by Professors Peter G. Stock, M.D., Ph.D. and Minnie M. Sarwal [...]

  • Transplant Drug Sirolimus May Help Eliminate Lingering HIV infections

    UCSF Transplant Surgery - April 01, 2014
    "Researchers studying the effects of immune suppressant drugs on transplant patients with HIV have made a surprising discovery: A drug intended to hobble the body's defense system may actually help destroy dormant reservoirs of the virus that causes AIDS In a paper published this week in the American Journal of Transplantation, authors found that when a small group of transplant patients received the drug sirolimus, they experienced a two- to threefold drop in HIV levels, whereas patients who [...]

  • Dr. Peter Stock Instrumental in Passage of Bill Lifting Research Ban on HIV Organ Transplants

    UCSF Transplant Surgery - December 05, 2013
    Peter Stock And President Obama
    President Barack Obama signs S. 330: HIV Organ Policy Equity Act during a signing ceremony in the Oval Office, Nov. 21, 2013. (Official White House Photo by Lawrence Jackson) MSNBC reports on President Obama's signing of  a bill that ended a decades-old policy that banned organ donations from one HIV-positive person to another. A clinical trial led by UCSF transplant surgeon Peter G. Stock, M.D., Ph.D. was instrumental to the passage of the Hope Act that lifted the ban. The HIV Organ [...]

  • For Type 1 Diabetes, Islet Transplantation Gains Momentum

    UCSF Transplant Surgery - November 14, 2013
    UCSF News, reporting on the 14th World Congress of the International Pancreas and Islet Transplant Association (IPITA), highlighed improving results in  islet cell transplantation: For the worst cases of type 1 diabetes, islet transplantation already has freed hundreds of people from complete dependence on insulin and from life-threatening consequences of the disease. "However, the procedure still is regarded as experimental by the U.S. Food and Drug Administration (FDA). Islets are [...]

  • Doctor: No problems after Antioch toddler undergoes kidney and liver transplant

    UCSF Transplant Surgery - June 05, 2013
    "The sun wasn't up at 5 o'clock Wednesday morning, but a new day had already dawned for Matthew Ouimet. Matthew, a 2-year-old Antioch boy who had waited 15 months for a life-sustaining kidney and liver transplant, had his new organs. Dr. John Roberts took the lead on the liver transplant, and Dr. Peter Stock, who handled the kidney procedure in a 12-hour surgery that began around 6 p.m. Tuesday, delivered the good news to parents Kristi and Kelly Ouimet and a half-dozen family members who spent [...]

  • UCSF Study Prompts Calls to Repeal Ban on Transplanted Organs from HIV-Positive Donors

    UCSF Transplant Surgery - April 11, 2011
    Last year, a team led by Dr. Peter Stock of UCSF reported on results from a large multicenter study testing the safety and feasibility of transplanting kidneys where both the donor and recipients were infected with HIV, the virus that causes AIDS. The results, reported in the New England Journal of Medicine, showed that the recipients survived nearly as long as non-HIV infected recipients of kidney transplants. As a result of the Stock-led trial, and a just-published paper from Johns Hopkins [...]

  • UCSF Liver Transplant Team Shares Expertise in Latin America

    UCSF Transplant Surgery - March 23, 2011
    Niemann
    "Previously, Uruguay had tried to go it alone, but high mortality rates soon caused doctors to shut the program down. After their initial visit, the UCSF transplant team, including anesthesiologist Claus U. Niemann, MD (pictured first), and surgeons Ryutaro Hirose, MD (pictured second), and Peter Stock, MD, PhD, (pictured third) continued to consult with the team in Uruguay, guiding them through everything from patient selection procedures to the use of immunosuppressive medications [...]

  • Kidney Transplants Found Safe in HIV Patients

    UCSF Transplant Surgery - November 18, 2010
    "People infected with the AIDS virus can safely receive a kidney transplant, researchers reported on Wednesday. The finding, published in Thursday's New England Journal of Medicine, is good news for people with HIV who are more prone to kidney disease, in part because of the drugs they must take to stay healthy. Before drug cocktails turned HIV from a death sentence to a chronic condition, patients were not eligible to receive a kidney. But now they can. 'Patient and graft survival are really [...]

  • Improving the Outlook for Simultaneous Pancreas-Kidney Transplants

    UCSF Transplant Surgery - February 01, 2005
    "The body's rejection of transplanted organs and tissues is an unfortunate risk of transplant surgery. Historically, rejection rates in a simultaneous pancreas-kidney (SPK) transplant have been as high as 80% and, in 2001, averaged nearly 20%. ........Diabetes Center surgeons Peter Stock, (left) and Chris Freise (right) have been pioneering new methods of immunosuppression for SPK transplants that do not rely upon steroids, with great success...... " Read Full Diabetes Center [...]

 

 
Site Directory
    X